$105M In Milestone Payment
Merck Paying $31M Up Front In Dynavax HBV Vaccine Deal
Dynavax Technologies Corp.'s licensing deal with Merck & Co. Inc. to develop the Phase III hepatitis B virus vaccine Heplisav provides $31.5 million up front with $105 million in potential milestone payments plus royalties, as Dynavax continues managing the pivotal studies and the two firms gear up for a biologics license application filing, possibly in the first quarter of 2009. (BioWorld Today)
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.